Amgen Inc. $AMGN Stock Position Increased by DCF Advisers LLC

DCF Advisers LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 53.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 10,500 shares of the medical research company’s stock after buying an additional 3,675 shares during the period. Amgen accounts for 1.4% of DCF Advisers LLC’s investment portfolio, making the stock its 28th largest position. DCF Advisers LLC’s holdings in Amgen were worth $2,932,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of AMGN. Insigneo Advisory Services LLC lifted its holdings in Amgen by 5.8% in the 2nd quarter. Insigneo Advisory Services LLC now owns 2,922 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 160 shares during the last quarter. CreativeOne Wealth LLC raised its holdings in shares of Amgen by 4.1% in the 2nd quarter. CreativeOne Wealth LLC now owns 15,338 shares of the medical research company’s stock worth $4,282,000 after purchasing an additional 600 shares in the last quarter. Act Two Investors LLC acquired a new stake in Amgen during the second quarter valued at approximately $12,905,000. Atlantic Family Wealth LLC boosted its holdings in Amgen by 16.4% during the second quarter. Atlantic Family Wealth LLC now owns 932 shares of the medical research company’s stock worth $260,000 after buying an additional 131 shares in the last quarter. Finally, Summit Global Investments grew its position in Amgen by 3.0% in the second quarter. Summit Global Investments now owns 5,026 shares of the medical research company’s stock worth $1,403,000 after buying an additional 147 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. The trade was a 11.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 10,908 shares of company stock valued at $3,674,966 in the last quarter. Company insiders own 0.76% of the company’s stock.

Amgen Trading Up 0.4%

Shares of NASDAQ AMGN opened at $337.54 on Monday. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. Amgen Inc. has a one year low of $253.30 and a one year high of $345.84. The business has a 50-day moving average price of $300.99 and a two-hundred day moving average price of $292.58. The firm has a market capitalization of $181.76 billion, a PE ratio of 27.60, a PEG ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be given a $2.38 dividend. The ex-dividend date is Friday, November 21st. This represents a $9.52 dividend on an annualized basis and a yield of 2.8%. Amgen’s dividend payout ratio is presently 73.57%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of recent research reports. Raymond James Financial began coverage on Amgen in a research report on Wednesday, September 3rd. They set a “market perform” rating for the company. DZ Bank upped their target price on Amgen from $335.00 to $364.00 in a report on Monday, November 10th. HSBC lifted their price target on Amgen from $343.00 to $381.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a research note on Tuesday, November 11th. Finally, UBS Group dropped their target price on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $319.90.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.